Portola Pharmaceuticals (PTLA +10.1%) moves up after saying late yesterday that it had entered...

|About: Portola Pharmaceuticals (PTLA)|By:, SA News Editor

Portola Pharmaceuticals (PTLA +10.1%) moves up after saying late yesterday that it had entered into a clinical collaboration agreement with Daiichi Sankyo (DSNKY.PK) to conduct a Phase 2 study of its investigational Factor Xa inhibitor antidote PRT4445, or andexanet alfa. The study will at several different doses to reverse the anticoagulant effects of Daiichi Sankyo's oral direct Factor Xa inhibitor edoxaban in healthy volunteers.